Articles

Cancer mortality projections through 2026 among young adults in 15 upper-middle and high-income countries with focus on colorectal cancer

Silvia Mignozzi, Claudia Santucci, Gianfranco Alicandro, et al. Cancer Causes Control. 2026 Apr 3;37(5):79

An increasing cancer incidence has been observed among recent generations over the last decade. However, apart from colorectal cancer, these increases were not associated with rises in mortality. We extracted death counts for individuals aged 25-49 from the WHO Mortality Database and population data from the UN Wo... Read More

12 May, 2026

Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers

Zachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, et al. Lancet Oncol. 2026 May;27(5):560-568

Cancer survival has improved in many countries in recent decades, but large disparities remain globally. Understanding the effects of workforce shortages, stage at diagnosis, and broader health system barriers on poor survival is important for the design and evaluation of policy interventions to improve cancer sur... Read More

12 May, 2026

Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021

Yingying Li, Wenfu Song, Ping Gao, et al. BMC Cancer. 2025 Feb 24;25(1):330

Female breast cancer, cervical cancer, uterine cancer, and ovarian cancer (FBCUO) pose a significant threat to global public health. Incidence, age-standardized incidence rate (ASIR), deaths, age-standardized mortality rate (ASMR), disability-adjusted life years (DALYs), age-standardized rate of DALYs (ASDR), and ... Read More

12 May, 2026

Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021

Wenhui Ren, Xiangyu Guo, Zheng Liu, et al. Cancer. 2025;e35712. 1-11 wileyonlinelibrary.com/journal/cncr

Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. The year‐ and age‐specific estimates of the incidence, mortality, and disability‐adjusted life‐years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were gener... Read More

12 May, 2026

The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050 a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Cancer Collaborators. Lancet. 2025 Oct 11;406(10512):1565-1586

In 2023, excluding non-melanoma skin cancers, there were 18·5 million incident cases of cancer and 10·4 million deaths, contributing to 271 million DALYs globally. Of these, 57·9% of incident cases and 65·8% of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group c... Read More

12 May, 2026

Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Breast Cancer Collaborators. Lancet Oncol. 2026 Mar;27(3):302-326

Breast cancer is a leading cause of mortality and morbidity among females worldwide. In 2023, there were an estimated 2.30 million breast cancer incident cases, 764 000 deaths, and 24.1 million DALYs among females globally. In the World Bank low-income group, where a low age-standardised incidence rate (ASIR) was ... Read More

12 May, 2026

A Population-Based Study of Genes Previously Implicated in Breast Cancer

Chunling Hu, Steven N Hart, Rohan Gnanaolivu et al. N Engl J Med. 2021 Feb 4;384(5):440-451

In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Can... Read More

15 Apr, 2026

Tissue-agnostic cancer therapies: promise, reality, and the path forward

Vivek Subbiah. Nature Communications. (2025) 16:4972

Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting moleculardrivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progressdepends on universal genomic testing, an oncoge... Read More

15 Apr, 2026

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P Patel, Megan Othus, Yuanbin Chen et al. N Engl J Med. 2023 Mar 2;388(9):813-823

In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (2... Read More

15 Apr, 2026

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Christian U Blank, Minke W Lucas, Richard A Scolyer et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708

In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab. A total of 423 patients underwent randomization. At a median follow-up of 9.9 months, th... Read More

15 Apr, 2026